Publications by authors named "Andrew M Haydon"

Claim this Profile
M
Malignancy risk and mortality after lung transplantation: A single-institution experience over 31 years.
Hui-Ling Yeoh, Helen Shingles, Eldho Paul, Bronwyn J Levvey, Max Schwarz, Andrew M Haydon

JHLT Open· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.
Oliver John Kennedy, Nina Glassee, Michal Kicinski, Christian U Blank, Georgina V Long, Andrew M Haydon

Eur J Cancer· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.
Oliver John Kennedy, Michal Kicinski, Sara Valpione, Sara Gandini, Stefan Suciu, Andrew M Haydon

Eur J Cancer· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune-related adverse events secondary to immunotherapy in oncology: A guide for general practice.
Hui-Ling Yeoh, Karen Freilich, Mark Voskoboynik, Maggie Moore, Miles C Andrews, Andrew M Haydon

Aust J Gen Pract· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma.
Prachi Bhave, Tasnia Ahmed, Serigne N Lo, Alexander Shoushtari, Anne Zaremba, Andrew M Haydon

J Immunother Cancer· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.
Oliver J Kennedy, Michal Kicinski, Sara Valpione, Sara Gandini, Stefan Suciu, Andrew M Haydon

Eur J Cancer· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diet and risk of gastro-oesophageal reflux disease in the Melbourne Collaborative Cohort Study.
Sabrina E Wang, Allison M Hodge, S Ghazaleh Dashti, Suzanne C Dixon-Suen, Hazel Mitchell, Andrew M Haydon

Public Health Nutr· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial.
Alexander M M Eggermont, Christian U Blank, Mario Mandalà, Georgina V Long, Victoria G Atkinson, Andrew M Haydon

Lancet Oncol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.
Andrew Bottomley, Corneel Coens, Justyna Mierzynska, Christian U Blank, Mario Mandalà, Andrew M Haydon

Lancet Oncol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to E. Hindié.
Alexander M M Eggermont, Christian U Blank, Mario Mandala, Georgina V Long, Victoria G Atkinson, Andrew M Haydon

J Clin Oncol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic significance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies.
Jeanne Tie, Joshua D Cohen, Serigne N Lo, Yuxuan Wang, Lu Li, Andrew M Haydon

Int J Cancer· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial.
Alexander M M Eggermont, Christian U Blank, Mario Mandala, Georgina V Long, Victoria G Atkinson, Andrew M Haydon

J Clin Oncol· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognosis associated with cutaneous melanoma metastases.
Yan Pan, Andrew M Haydon, Catriona A McLean, Priska B B McDonald, John W Kelly

Australas J Dermatol· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expression of MUC2, MUC5AC, MUC5B, and MUC6 mucins in colorectal cancers and their association with the CpG island methylator phenotype.
Michael D Walsh, Mark Clendenning, Elizabeth Williamson, Sally-Ann Pearson, Rhiannon J Walters, Andrew M Haydon

Mod Pathol· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of socioeconomic status on survival from colorectal cancer in the Melbourne Collaborative Cohort Study.
Helen L Kelsall, Laura Baglietto, David Muller, Andrew M Haydon, Dallas R English

Soc Sci Med· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Ethnicity and risk for colorectal cancers showing somatic BRAF V600E mutation or CpG island methylator phenotype.
Dallas R English, Joanne P Young, Julie A Simpson, Mark A Jenkins, Melissa C Southey, Andrew M Haydon

Cancer Epidemiol Biomarkers Prev· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma.
Karl D Lewis, William A Robinson, Michael J Millward, Alex Powell, Timothy J Price, Andrew M Haydon

Invest New Drugs· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence of malignancies in heart and/or lung transplant recipients: a single-institution experience.
Sabine Roithmaier, Andrew M Haydon, Sherene Loi, Don Esmore, Ann Griffiths

J Heart Lung Transplant· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Body size and composition and risk of rectal cancer (Australia).
Robert J MacInnis, Dallas R English, Andrew M Haydon, John L Hopper, Dorota M Gertig

Cancer Causes Control· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Body size and composition and colon cancer risk in women.
Robert J MacInnis, Dallas R English, John L Hopper, Dorota M Gertig, Andrew M Haydon

Int J Cancer· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Red meat, chicken, and fish consumption and risk of colorectal cancer.
Dallas R English, Robert J MacInnis, Allison M Hodge, John L Hopper, Andrew M Haydon

Cancer Epidemiol Biomarkers Prev· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Body size and composition and colon cancer risk in men.
Robert J MacInnis, Dallas R English, John L Hopper, Andrew M Haydon, Dorota M Gertig

Cancer Epidemiol Biomarkers Prev· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Emerging pathways in colorectal-cancer development.
Andrew M M Haydon, Jeremy R Jass

Lancet Oncol· February 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis